Fund Details
Forepont Capital Partners
590 Madison Ave Fl 21, New York City, New York, 10022, United States
Overview
Investment portfolio
8rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Exeliom | Oct 2025Participated | $3 MSeries A | |
Okeiro | Apr 2025Led | $12 MOther Equity | |
GPN Vaccines | Jun 2024Led | $12 MOther Equity | |
basecamp vascular | Dec 2023Led | $6 MSeries A | |
Precision Neuroscience | Jan 2023Led | $41 MSeries B | |
GPN Vaccines | Jan 2023Led | $6 MSeries A | |
Synchron | Dec 2022Participated | $75 MSeries C | |
Synchron | Jun 2021Participated | $40 MSeries B | |
Exeliom | Oct 2025Participated | $3 MSeries A | |
Okeiro | Apr 2025Led | $12 MOther Equity | |
GPN Vaccines | Jun 2024Led | $12 MOther Equity | |
basecamp vascular | Dec 2023Led | $6 MSeries A | |
Precision Neuroscience | Jan 2023Led | $41 MSeries B | |
GPN Vaccines | Jan 2023Led | $6 MSeries A | |
Synchron | Dec 2022Participated | $75 MSeries C | |
Synchron | Jun 2021Participated | $40 MSeries B |
8 Items
8
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 2 | 1 |
| Series B | 1 | 1 |
| Series C+ | 0 | 1 |
| Other Equity | 2 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 2 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 8 |
| Hardware & Robotics | 3 |
| Marketing & Advertising | 2 |
| Manufacturing | 2 |
| Space & Frontier Tech | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 2 |
| $10M-$25M | 2 |
| $25M-$50M | 2 |
| $50M-$100M | 1 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 3 |
| Europe | 3 |
| Australia | 2 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alumni Ventures | 2 |
| ID8 Investments | 2 |
| Khosla Ventures | 2 |
| NeuroTechnology Investors | 2 |
| re.Mind Capital | 2 |
| Shanda Group | 2 |
| University of Melbourne | 2 |
| Alven | 1 |
| ARCH Venture Partners | 1 |
| B Capital Group | 1 |
| Bezos Expeditions | 1 |
| Biocodex | 1 |
| Crescent Ventures | 1 |
| Draper Associates | 1 |
| Gates Frontier | 1 |
| General Advance | 1 |
| Greenoaks Capital | 1 |
| Kern Capital | 1 |
| MEDCO | 1 |
| METIS | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 5 | 63% |
| Participating | 3 | 38% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 60% |
| Co-led | 2 | 40% |